Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its... see more

Recent & Breaking News (NDAQ:GILD)

European Medicines Agency Validates Gilead's Marketing Application for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Chronic Hepatitis C Infection

Business Wire March 27, 2014

Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case

GlobeNewswire March 24, 2014

King: How the Oncology Drug Development Machine Builds Biotech Wealth

Equities.com March 17, 2014

Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe

GlobeNewswire March 14, 2014

Better, Faster, Cheaper-You Can Have All Three in Medtech: Ben Haynor

Equities.com March 12, 2014

Gilead Prices $4 Billion of Senior Unsecured Notes

Business Wire March 4, 2014

Gilead Sciences to Present at the 34th Cowen & Co. Healthcare Conference on Monday, March 3

Business Wire February 28, 2014

Aethlon Medical Expands Clinical Network Through DaVita Agreement

ACCESS Newswire February 26, 2014

Gilead Sciences to Present at the RBC Capital Markets 2014 Global Healthcare Conference on Wednesday, February 26

Business Wire February 25, 2014

Benchmark Indices Remain Flat as Nasdaq Jumps to Open Week of Trading

Equities.com February 18, 2014

Stocks Rally For Another Up Week on Wall Street

Equities.com February 14, 2014

Galectin Therapeutics Leaps Ahead with SBH Sciences Partnership

ACCESS Newswire February 13, 2014

TrendingWallStreet.com Begins Market Coverage on ITMN, BECC, EDXC, and GILD

ACCESS Newswire February 11, 2014

Gilead Sciences to Present at Two Upcoming Investor Conferences

Business Wire February 10, 2014

Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C

Business Wire February 10, 2014

RDInvesting Provides Investors with Free In-Depth Equity Reports on AGN, FRX, GILD and PFE

ACCESS Newswire February 5, 2014

TrendingWallStreet.com Starts Covering JCP, GILD, ICBU, and MLCG

ACCESS Newswire February 5, 2014

Gilead Sciences Announces Fourth Quarter and Full Year 2013 Financial Results

Business Wire February 4, 2014

Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India

PR Newswire January 31, 2014

Gilead Sciences to Release Fourth Quarter and Year End 2013 Financial Results on Tuesday, February 4, 2014

Business Wire January 28, 2014